Monday, October 27, 2025
- 10:30AM-12:30PM
-
Abstract Number: 1276
Mental Health Screening Implementation for Pediatric Rheumatology Patients at a Tertiary Academic Medical Center
(1272–1305) Pediatric Rheumatology – Clinical Poster II- 10:30AM-12:30PM
-
Abstract Number: 1592
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
(1592–1611) Vasculitis – ANCA-Associated Poster II- 10:30AM-12:30PM
-
Abstract Number: 0968
Mesenchymal Stromal Cells in Systemic Sclerosis are Dysfunctional and Have a Profibrotic and Senescent Phenotype
(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I- 10:30AM-12:30PM
-
Abstract Number: 1119
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
(1088–1122) Immunological Complications of Medical Therapy Poster- 10:30AM-12:30PM
-
Abstract Number: 1332
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1051
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
(1038–1054) Health Services Research Poster II- 10:30AM-12:30PM
-
Abstract Number: 1011
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
(1007–1037) Epidemiology & Public Health Poster II- 10:30AM-12:30PM
-
Abstract Number: 1141
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I- 10:30AM-12:30PM
-
Abstract Number: 1442
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1367
Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
(1347–1375) Rheumatoid Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1200
Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)
(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 1024
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
(1007–1037) Epidemiology & Public Health Poster II- 10:30AM-12:30PM
-
Abstract Number: 1328
Mortality Trends of Hypertension in Patients with Rheumatoid Arthritis in the United States (1999–2020)